Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia

References

• Almoallim H, Hassan R, Cheikh M, et al. Rheumatoid arthritis Saudi database (RASD): disease characteristics and remission rates in a tertiary care center. Open Access Rheumatol. 2020;12:139–145. doi:10.2147/OARRR.S260426.
   PubMed Web of Science ®Google Scholar
• Abu Al-Fadl EM, Ismail MA, Thabit M, et al. Assessment of health-related quality of life, anxiety and depression in patients with early rheumatoid arthritis. Egypt Rheumatol. 2014;36(2):51–56. doi:10.1016/j.ejr.2013.12.004.
   Google Scholar
• Almoallim HM, Alharbi LA. Rheumatoid arthritis in Saudi Arabia. Saudi Med J. 2014;35(12):1442–1454.
   PubMed Web of Science ®Google Scholar
• Calabresi E, Petrelli F, Bonifacio AF, et al. One year in review 2018: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2018;36(2):175–184.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Davis JM, 3rd, Crowson CS, et al. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379–385. doi:10.1007/s11926-010-0117-y.
   PubMedGoogle Scholar
• Katchamart W, Narongroeknawin P, Chanapai W, et al. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3(1):34. doi:10.1186/s41927-019-0080-9.
   PubMedGoogle Scholar
• Almutairi KB, Nossent JC, Preen DB, et al. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021;48(5):669–676. doi:10.3899/jrheum.200367.
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–136. doi:10.1016/j.autrev.2004.09.002.
   PubMed Web of Science ®Google Scholar
• Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070. doi:10.3389/fphar.2018.01070.
   PubMed Web of Science ®Google Scholar
• Al-Dalaan A, Al Ballaa S, Bahabri S, et al. The prevalence of rheumatoid arthritis in the Qassim region of Saudi Arabia. Ann Saudi Med. 1998;18(5):396–397. doi:10.5144/0256-4947.1998.396.
   PubMed Web of Science ®Google Scholar
• Sanmartí R, Ruiz-Esquide V, Hernández MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Curr Top Med Chem. 2013;13(6):698–704. doi:10.2174/15680266113139990092.
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French society for rheumatology for managing rheumatoid arthritis. Joint Bone Spine. 2014;81(4):287–297. doi:10.1016/j.jbspin.2014.05.002.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715.
   PubMed Web of Science ®Google Scholar
• Janus Kinase Inhibitors for Rheumatoid Arthritis. Effectiveness and Value October 11, 2019. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_RA_Draft_Evidence_Report_101119.pdf.
   Google Scholar
• Singh JA, Saag KG, Bridges SL, Jr., et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2015;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology (Oxford). 2000;39 Suppl 1(suppl_1):30–35. doi:10.1093/oxfordjournals.rheumatology.a031492.
   PubMedGoogle Scholar
• Bykerk VP, Massarotti EM. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012;51(Suppl 6):vi16–20. doi:10.1093/rheumatology/kes281.
   PubMedGoogle Scholar
• Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981;24(10):1308–1315. doi:10.1002/art.1780241012.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625–2636. doi:10.1002/art.21235.
   PubMed Web of Science ®Google Scholar
• Lillegraven S, Prince FH, Shadick NA, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis. 2012;71(5):681–686. doi:10.1136/ard.2011.154625.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 2008;59(10):1371–1377. doi:10.1002/art.24123.
   PubMed Web of Science ®Google Scholar
• Treating Rheumatoid Arthritis with Disease-Modifying Drugs (DMARDs). Available from: https://www.webmd.com/rheumatoid-arthritis/dmard-rheumatoid-arthritis-treatment.
   Google Scholar
• Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis. 2009;68(7):1086–1093. doi:10.1136/ard.2008.094474.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. doi:10.1136/ard-2022-223356.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–939. doi:10.1002/acr.24596.
   PubMed Web of Science ®Google Scholar
• Omair MA, Al Rayes H, Khabsa J, et al. Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American college of rheumatology guidelines. BMC Rheumatol. 2022;6(1):70. doi:10.1186/s41927-022-00301-y.
   PubMedGoogle Scholar
• Massalska M, Maslinski W, Ciechomska M. Small molecule inhibitors in the treatment of rheumatoid arthritis and beyond: latest updates and potential strategy for fighting COVID-19. Cells. 2020;9(8):1876. doi:10.3390/cells9081876.
   PubMed Web of Science ®Google Scholar
• Pope J, Sawant R, Tundia N, et al. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther. 2020;37(5):2356–2372. doi:10.1007/s12325-020-01303-3.
   PubMed Web of Science ®Google Scholar
• Rinvoq FDA Approval History. Available from: https://www.drugs.com/history/rinvoq.html.
   Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–975. doi:10.1136/ard.2009.126532.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, Double-Blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–1800. doi:10.1002/art.41032.
   PubMed Web of Science ®Google Scholar
• Upadacitinib for treating moderate to severe rheumatoid arthritis. 2020. Available from: https://www.nice.org.uk/guidance/ta665/documents/129.
   Google Scholar
• Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80(3):304–311. doi:10.1136/annrheumdis-2020-218510.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Curtis JR, Charles-Schoeman C, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;82(9):1130–1141. doi:10.1136/annrheumdis-2019-215764.
   Google Scholar
• Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779–787. doi:10.1080/14397595.2020.1782049.
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol. 2020;79(8):785–796. doi:10.1007/s00393-020-00750-1.
   PubMed Web of Science ®Google Scholar
• Jadhav S, Yang Y. Pms17 cost effectiveness analysis of upadacitinib and methotrexate for patients with methotrexate-resistant rheumatoid arthritis. Value Health. 2020;23:S217. doi:10.1016/j.jval.2020.04.704.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Combe B, Szekanecz Z, et al. POS0677 Consistency in time to response with upadacitinib as monotherapy or combination therapy and across patient populations with rheumatoid arthritis. ACR Convergence; 2021.
   Google Scholar
• Kerschbaumer A, Smolen JS, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):778–786. doi:10.1136/annrheumdis-2020-217163.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71(1):2–29. doi:10.1002/acr.23789.
   PubMed Web of Science ®Google Scholar
• Bergman M, Tundia N, Yang M, et al. Economic benefit from improvements in quality of life with upadacitinib: comparisons with tofacitinib and methotrexate in patients with rheumatoid arthritis. Adv Ther. 2021;38(12):5649–5661. doi:10.1007/s12325-021-01930-4.
   PubMed Web of Science ®Google Scholar
• ICER Releases Evidence Report on JAK Inhibitors to Treat Rheumatoid Arthritis. [Internet]. Available from: https://icer.org/news-insights/press-releases/jak_inhibitor_evidence_report/.
   Google Scholar
• CADTH Common Drug Reviews. Clinical review report: upadacitinib (rinvoq): (AbbVie): indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright © 2020 Canadian Agency for Drugs and Technologies in Health; 2020.
   Google Scholar
• Maraiki F, Bazarbashi S, Scuffham P, et al. Methodological approaches to cost-effectiveness analysis in Saudi Arabia: what can we learn? A systematic review. MDM Policy Pract. 2022;7(1):23814683221086869. doi:10.1177/23814683221086869.
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10–31. doi:10.1016/j.jval.2021.10.008.
   PubMed Web of Science ®Google Scholar
• Saudi Central Bank. Finance and exchange rate. Available from: https://www.sama.gov.sa/en-US/FinExc/Pages/Currency.aspx.
   Google Scholar
• Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021;23(1):9. doi:10.1186/s13075-020-02387-6.
   PubMedGoogle Scholar
• Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib in japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford). 2020;59(11):3303–3313. doi:10.1093/rheumatology/keaa084.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Sawant R, Garg V, et al. A Matching-Adjusted indirect comparison of upadacitinib versus tofacitinib in adults with moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2021;8(1):167–181. doi:10.1007/s40744-020-00257-w.
   PubMed Web of Science ®Google Scholar
• Park MC, Matsuno H, Kim J, et al. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther. 2019;21(1):122. doi:10.1186/s13075-019-1910-2.
   PubMed Web of Science ®Google Scholar
• Targeted immune modulators for rheumatoid arthritis: effectiveness & value. Available from: http://icerorg.wpengine.com/wp-content/uploads/2020/10/NE_CEPAC_RA_Evidence_Report_FINAL_040717.pdf.
   Google Scholar
• Hernández Alava M, Wailoo A, Wolfe F, et al. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Making. 2014;34(7):919–930. doi:10.1177/0272989X13500720.
   PubMed Web of Science ®Google Scholar
• Boytsov N, Harrold LR, Mason MA, et al. Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients. Curr Med Res Opin. 2016;32(12):1959–1967. doi:10.1080/03007995.2016.1222515.
   PubMed Web of Science ®Google Scholar
• Boonen A, Matricali GA, Verduyckt J, et al. Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery. Ann Rheum Dis. 2006;65(5):694–695. doi:10.1136/ard.2005.047175.
   PubMed Web of Science ®Google Scholar
• Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16(1):R56. doi:10.1186/ar4491.
   PubMed Web of Science ®Google Scholar
• Chaparro Del Moral R, Rillo OL, Casalla L, et al. Work productivity in rheumatoid arthritis: relationship with clinical and radiological features. Arthritis. 2012;2012:137635–137637. doi:10.1155/2012/137635.
   PubMedGoogle Scholar
• General Authority for Statistics. Labor market statistics; 2020. Available from: https://www.stats.gov.sa/sites/default/files/LM_2Q2020%20%28Press%20release_EN%20%29_2.pdf.
   Google Scholar
• Based on World Bank estimate of GDP per capita in KSA for 2019. Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=SA.
   Google Scholar